OraPharma, a leading oral care company of Bausch Health Companies Inc. (NYSE.TSX:BHC), today announced the U.S. launch of the MyPerioHealth app, a first-of-its kind interactive oral health educational tool that allows patients in conjunction with their dental professionals a quick and easy way to understand the stage and grade of periodontal disease on a single, digital platform at the point of care.
“The MyPerioHealth education app was designed as a resource for dental professionals when using the Periodontal Staging and Grading Guidelines established by the American Academy of Periodontology to help encourage dialogue and offer an interactive oral health assessment in a patient friendly, portable way,” said Dinesh Guglani, vice president and general manager, OraPharma. “By responding to a series of short questions, a patient and their dental care professional can obtain a wealth of important information regarding the patient’s periodontal health status, including the stage and grade, which are vital for treatment planning and determining the maintenance interval to help manage the disease.”
The AAP Guidelines are intended for patients who have already been diagnosed with periodontitis. The MyPerioHealth app complements manual staging and grading by streamlining data collection and automating calculations using the American Academy of Periodontology guidelines. The app will help increase patients’ awareness of gum disease by encouraging dialogue and collaboration between dental professionals and their patients.
“The MyPerioHealth™ app will help enhance the understanding of periodontal disease by providing patients with the ability to have greater understanding and ownership of their disease. Armed with their periodontal score and the ramifications of unchecked periodontal disease, we believe patients will be more accepting of the treatment recommendations they receive from their doctors.” Guglani continued.
Designed for use on a tablet or cell phone, the MyPerioHealth™ app is available on both iOS and Android platforms. It can be downloaded from the Google Play Store, Apple App Store or Amazon Appstore. A web-based version can also be accessed at www.myperiohealth.com.
About OraPharma
OraPharma, a leading oral care company of Bausch Health Companies Inc., is dedicated to developing innovative solutions in oral care to support dental health care professionals and patients. By focusing on improving patients’ lives through the connection between oral care and overall health, OraPharma offers a comprehensive suite of products that help address patients’ oral health concerns.
These products include ARESTIN® (minocycline HCl) Microspheres, 1 mg, NeutraSal® (supersaturated calcium phosphate rinse) and XERESE® (acyclovir and hydrocortisone) cream 5%/1%. For more information on OraPharma, visit www.orapharma.com.
Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements.
These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
